Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PDS Biotechnology Corp | s001066x1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 12, 2015
Edge Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
001-37568
|
26-4231384
|
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
200 Connell Drive, Suite 1600
Berkeley Heights, NJ 07922
(800) 208-3343
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On October 12, 2015, Edge Therapeutics, Inc. issued a press release announcing the receipt of orphan drug designation for EG-1962, its lead product candidate, from the European Commission. A copy of the press release is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
|
Exhibit
Number |
|
Description
|
|
99.1
|
Press Release, dated October 12, 2015.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: October 13, 2015
|
Edge Therapeutics, Inc.
|
||
|
|
|
||
|
|
|
By:
|
/s/ Andrew J. Einhorn
|
|
|
|
|
Name: Andrew J. Einhorn
|
|
|
|
|
Title: Chief Financial Officer
|
3
EXHIBIT INDEX
|
Exhibit
Number |
Description
|
|
|
99.1
|
Press Release, dated October 12, 2015.
|
4